Health Care Supplies

ORBUSNEICH

ORBUSNEICH released FY2025 Q3 earnings on March 12 (BJT), actual revenue HKD 377.09 M, actual EPS HKD 0.1042

ORBUSNEICH released FY2025 9 Months Earnings on March 12, 2026 (BJT), with actual revenue of HKD 1.03 B and EPS of HKD 0.2918

ORBUSNEICH released FY2025 earnings on March 12 Pre-Market (BJT), actual revenue HKD 1.407 B (forecast HKD 1.422 B), actual EPS HKD 0.3961 (forecast HKD 0.4031)

ORBUSNEICH released FY2025 Q4 earnings on March 12 Pre-Market (BJT), actual revenue HKD 376.95 M, actual EPS HKD 0.1042

ORBUSNEICH to Release FY2025 Annual Earnings on March 12, 2026 Pre-Market (BJT), Forecast Revenue HKD 1.393 B, EPS HKD 0.395

ORBUSNEICH released FY2025 Q1 earnings on August 15 (BJT), actual revenue HKD 324.98 M, actual EPS HKD 0.0933

ORBUSNEICH released FY2025 Semi-Annual earnings on August 15 Pre-Market (BJT), actual revenue HKD 652.91 M, actual EPS HKD 0.1875

ORBUSNEICH released FY2025 Q2 earnings on August 15 Pre-Market (BJT), actual revenue HKD 327.93 M, actual EPS HKD 0.0941

ORBUSNEICH to Release FY2025 Semi-Annual Earnings on August 15, 2025 (BJT)

Jiali Medical Reports 2024 Sales Performance

ORBUSNEICH released FY2024 Q3 earnings on March 7 (BJT), with actual revenue of 331.01 M HKD and EPS of 0.0983 HKD

ORBUSNEICH released FY2024 9 Months Earnings on March 7 (BJT), with actual revenue of 947.87 M HKD and EPS of 0.2763 HKD

ORBUSNEICH released FY2024 annual earnings on March 7 After-Market (BJT), actual revenue 1.279 B HKD (forecast 1.25 B HKD), actual EPS 0.3748 HKD (forecast 0.3849 HKD)

ORBUSNEICH released FY2024 Q4 earnings on March 7 After-Market (BJT), actual revenue 330.75 M HKD, actual EPS 0.0982 HKD

Yejv Medical Announces 2024 Annual Results, Revenue of $164 Million, Up 6.6% Year-on-Year

ORBUSNEICH to Release FY2024 Earnings on March 7 After-Market (BJT), Forecast Revenue 1.25 B HKD, EPS 0.3855 HKD

Yiju Medical Proposes to Revoke Existing General Mandate and Grant New General Mandate

Yiju Medical releases six-month performance as of June 30, 2024

Yejuyi Medical expects a year-on-year decrease in profit of more than 20% in the first half of 2024

Yiju Medical releases 2023 annual performance

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

Ordinary dividend (cash)

Ex Date: 2026.06.10, Cash dividend 0.12 HKD

06929

159102

520880

513700

516930

159316

562600

517110

159898

159883

Yesterday's closing price for ORBUSNEICH was HKD 4.5, with a trading volume of approximately HKD 6.85 million, which is considered a normal level of activity among small and mid-cap medical device stocks. The MACD daily line formed a golden cross above the zero axis, a signal typically viewed as a technical confirmation of a shift in the short-term trend from consolidation to a bullish bias, indicating that buying power is gathering in phases. From recent trends, the stock price has gradually stabilized and rebounded from previous lows, with short-term moving averages beginning to turn upward. On the news front, the medical device sector has recently received multiple policy benefits. The domestic medical equipment upgrade policy continues to advance, coupled with the logic of going overseas, leading to increased attention on Hong Kong-listed medical supplies. Major stocks in the pharmaceutical sector, such as Innovent Biologics and CanSino Biologics, maintain high trading levels, indicating that capital enthusiasm for the healthcare sector remains strong. ORBUSNEICH focuses on the field of coronary intervention devices, and under the dual drive of domestic substitution and overseas expansion, the industry's prosperity is expected to continue to rise. From a technical perspective, the area around HKD 4.5 is an important consolidation platform for ORBUSNEICH recently, and the appearance of the MACD golden cross suggests that the balance between bulls and bears is tilting towards the bulls. Short-term moving averages have started to turn upward from a flat position; if there is a subsequent volume breakout above recent highs, the upward space is expected to further open up. However, the current trading volume of HKD 6.85 million is still relatively low, and signs of large capital entering the market are not yet apparent. In terms of risk, small-cap medical device stocks have limited liquidity, and intraday volatility may be significant, while industry policies such as centralized procurement and price reductions may impact the company's profitability. The technical signals are somewhat positive, but further confirmation of increased volume is needed

Technical Forecast

Huaan Hang Seng Biotech ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Penghua CSI HK Connect Health Care Composite ETF

Minsheng Royal CSI Biotechnology Theme ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC CSI All Share Health Care Devices ETF

Guotai CSI Hugangshen Innovative Drugs Industry ETF

China Merchants CSI All Share Medical Apparatus and Instruments ETF

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

INNOVENT BIO

AKESO

Pre-market trend | ORBUSNEICH (6929.HK) 5/11 Medical devices warming up, are low-level bullish signals emerging?

CICC analyst maintained a Buy rating on OrbusNeich Medical Group Holdings Limited yesterday and set a price target of HK$5.30.Claim 70% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential The word on The Street in general, suggests a Moderate Buy analyst consensus rating for OrbusNeich Medical Group Holdings Limited with a HK$5.30 average price target.

Tip Ranks

OrbusNeich Medical Group Holdings Limited (6929) Gets a Buy from CICC

ORBUSNEICH (6929) announced its results, declaring a final dividend of HKD 0.12 per share, a year-on-year increase of 20%. The company is considering the distribution of a regular interim dividend, but no specific ratio has been determined. The U.S. business is recovering rapidly and has entered the Middle Eastern market, with minimal impact from the U.S.-Iran war. The chairman stated that the company's advantage in the U.S. market lies in its global sales network. R&D expenses are expected to rise due to the initiation of clinical research in Japan. Revenue from the mainland has dropped by 13.9% due to the centralized procurement system, but the future impact is expected to be minor

Stheadline

ORBUSNEICH's final dividend is expected to increase by 20% to 12 cents, planning to declare a regular interim dividend

ORBUSNEICH's Chief Financial Officer stated that the company will actively consider distributing a mid-term dividend, as last year's special dividend received a positive response from shareholders. The company currently has USD 230 million in net cash and plans to explore acquisition opportunities and develop direct sales capabilities in Europe. The Chief Operating Officer expects continued growth in the Asia-Pacific and EMEA markets and anticipates the launch of more new products in the Japanese market. Although the Chinese market faces profit pressure from centralized procurement, the company believes that new products will drive revenue growth and deepen its presence in the Chinese market

AASTOCKS

ORBUSNEICH: Will actively consider distributing an interim dividend

516500

159837

159849

ORBUSNEICH announced its full-year results for the year ended December last year, with a revenue of USD 180 million, an increase of 10% year-on-year. The net profit was HKD 41.899 million, an increase of 5.5% year-on-year; earnings per share were HKD 5.09 cents. A final dividend of HKD 0.12 was declared, compared to HKD 0.10 in the same period last year

ChinaAMC CSI Biotechnology Theme ETF

E Fund CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

In the "Performance" report, ORBUSNEICH's annual net profit is USD 41.899 million, an increase of 5.5%, with a final dividend of HKD 0.12

WCGC

SBIO

Current Clinic has launched the nation's first healthcare network focused on cardiac arrhythmia care, completing its inaugural cardiac ablation procedures in Carlsbad, New Mexico. This marks the first time such procedures have been performed in an ambulatory surgery center in the state. The innovative model aims to provide comprehensive AFib treatment in a cost-effective setting, improving access for patients who previously traveled long distances for care. Current Clinic plans to expand its network to underserved communities nationwide, emphasizing the importance of specialized arrhythmia care.

prnewswire

VanEck Biotech ETF

WCG CLINICAL INC

Invesco Biotechnology & Genome ETF

SPDR S&P Health Equip

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

iShares Biotechnology ETF

iShares US Medical Devices

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

09:05 ETNation's First Cardiac Arrhythmia-Focused Healthcare Network Launches with New Mexico's First ASC-Based Ablation Procedures

OrbusNeich Medical Group Holdings Limited has announced its board composition effective January 22, 2026, which includes three executive directors, one non-executive director, and three independent non-executive directors. The company also updated its key board committees—Audit, Remuneration, and Nomination—clarifying the roles of directors. The latest analyst rating for OrbusNeich (HK:6929) is a Hold with a price target of HK$4.00. The company operates in the medical device sector, focusing on interventional cardiovascular solutions, with a current market cap of HK$3.19B.

OrbusNeich Sets 2026 Board Line-Up and Committee Roles

ORBUSNEICH's research and production base in Fuyang, Hangzhou, completed its structural topping on the 16th, becoming the largest integrated facility in the world. It is expected to be fully operational by 2027, with an annual production capacity increase of 2.4 million units, reaching approximately 4.5 million units. The base covers an area of 20,000 square meters, with an investment of about 430 million RMB, focusing on PCI and PTA interventional products, among others. Establishing the Hangzhou base will enhance production capacity, promote the application of new technologies, strengthen the stability of the global supply chain, and seize market growth opportunities

ORBUSNEICH's research and production base in Hangzhou has topped out

ORBUSNEICH(06929.HK)